INTRODUCTION
Radiofrequency ablation (RFA) is an endoscopic ablation technique for safe and effective eradication of Barrett's esophagus (BE) containing early neoplasia. In patients with visible lesions, RFA can be safely and effectively preceded by endoscopic resection (ER) of these focal lesions, yielding a specimen for histological staging and rendering the mucosa flat prior to RFA. Multicenter studies have reported complete eradication of all intestinal metaplasia and neoplasia in 77-100% of patients after RFA with or without ER. [1] [2] [3] [4] [5] [6] RFA treatment usually starts with a circumferential ablation with the balloon-based HALO 360 device (c-RFA), followed by focal ablation sessions with the smaller HALO 90 -device to treat residual BE. Generally, three endoscopic RFA sessions suffice to achieve complete conversion of the BE into squamous mucosa. Despite the good results of RFA treatment, sporadically, patients demonstrate a poor response to RFA. In our first five prospective RFA studies there were six patients (4%) in whom the RFA treatment protocol failed to achieve complete removal of all intestinal metaplasia and/or early neoplasia. [2] [3] [4] 6, 7 In these patients, the median regression percentage of Barrett's epithelium at 3 months after the initial c-RFA was 35% compared to 90% for other patients. We therefore hypothesized that there is a small subgroup of patients that demonstrates minimal regression of the BE epithelium at 3 months after the initial c-RFA, and that in some of these patients complete removal of BE will not be achieved despite repeated RFA sessions.
The early identification of patients with a high chance of failing RFA may influence the choice between RFA and other endoscopic treatment modalities such as complete stepwise endoscopic resection, a conservative approach with regular endoscopic followup, or surgery.
In this multicenter study, we prospectively collected baseline factors relating to patient characteristics, features of the Barrett's segment and technical aspects of the c-RFA procedure. These factors were subsequently related to the BE surface area regression at 3 months after c-RFA, to identify potential predictive factors for initial treatment response after c-RFA.
PATIENTS AND METHODS
Patients were eligible for c-RFA treatment if they met the following inclusion criteria: no worse than high-grade dysplasia (HGD) in flat type BE prior to RFA. Exclusion criteria were: visible lesions (i.e. nodularity) on high resolution endoscopy prior to RFA; in case of prior ER: ER specimens that demonstrated >T1sm1, positive deep resection margins, G3-G4 tumor differentiation, or presence of lymphatic/vascular invasion; signs of metastasis on endoscopic ultrasonography or computed tomography scanning of thorax and abdomen (in case of cancer); symptomatic dysphagia, or an esophageal inner diameter <18mm prior to RFA. [2] [3] [4] 6, 7 Radiofrequency ablation (RFA) RFA was performed using the HALO system (BÂRRX Medical, Sunnyvale, CA, USA) consisting of the HALO 360 -balloon-catheter for circumferential RFA and the smaller HALO 90 -electrode for focal ablation. 4, 8 Prior to RFA, the esophagus was evaluated using high-resolution endoscopy (HRE) and narrow band imaging (NBI) or Fuji Intelligent Chromo Endoscopy (FICE) or iScan (Pentax). The extent of the BE was registered according to the Prague C&M classification. 9 The number of BE islands and squamous islands in BE were noted. The presence and location of visible abnormalities and (relative) narrowing of the esophagus were documented. Still images with HRE and NBI were obtained for every 1-2 cm of the BE while pulling back from the top of the gastric folds. Initial c-RFA was performed using the HALO 360 -ballooncatheter, using two ablation passes (12J/cm2, 40Watt/cm2) and cleaning of the ablation zone and balloon-catheter after the first pass. 4, 8 After 3 months, the treatment effect was assessed during follow-up endoscopy with HRE and NBI. Again still images were obtained of every 1-2cm of the BE, and the percentage of BE regression was scored by the endoscopist. RFA was repeated every 2-3 months until complete endoscopic BE eradication was achieved. 4, 8 For persisting BE after a maximum of 5 RFA sessions (≤2 HALO 360 procedures), escape ER was performed. Once complete endoscopic BE eradication was achieved, 4Q/2cm biopsies were obtained throughout of the extent of the original BE and immediately distal (<5mm) to the neosquamocolumnar junction to document complete histological eradication of early neoplasia (CR-neoplasia) and IM (CR-IM). Patients were then scheduled for follow-up endoscopy at 6 months and annually thereafter.
Outcome assessment: Barrett's surface area regression percentage at 3 months.
The primary outcome measure was the percentage of visible BE surface regression at 3 months after the initial c-RFA session. We hypothesized that BE surface regression at 3 months (response after the first c-RFA session) is predictive of the final response at the end of the treatment period, defined by CR-neoplasia and CR-IM. 'Poor initial response' was defined as <50% BE surface regression at 3 months after c-RFA.
Secondary treatment outcomes measures were: CR-neoplasia, CR-IM, number of RFA sessions, duration of the RFA treatment period, escape treatment required to achieve CR.
Blinded scoring of the Barrett's surface area regression percentage.
The endoscopist who scored the Barrett's surface area regression at 3 months in 'real time' during the procedure was not blinded to patient history and features of the BE. We therefore performed an independent assessment by two endoscopists to guarantee an unbiased assessment.
The still images obtained at the initial c-RFA session (prior to c-RFA) and at the 3 months follow-up endoscopy (post-c-RFA) were placed in a PowerPoint presentation. Two experienced endoscopists (BW, ES) independently reviewed the PowerPoint presentation to estimate the Barrett's surface area regression at 3 months. They were informed on the baseline BE length, but were blinded to patient history, clinical features, images of previous endoscopies, and information on the technical features of the initial c-RFA treatment.
The endoscopists indicated if the endoscopic images allowed them to reliably estimate the surface area regression (scored as 'good', 'moderate' or 'poor'). For cases scored as 'poor' by either one of the endoscopists, the surface area regression as assessed in real-time during the 3 months follow-up endoscopy was used in the analysis. Cases for which the surface area regression scores of the two endoscopists differed ≥30% were reviewed during a consensus meeting to establish a single consensus-score. For all other cases, the mean of the two independent assessment scores of the surface area regression percentage was used in the analysis.
Potential predictors of poor initial response
Baseline variables were categorized as patient characteristics, BE characteristics, and treatment characteristics of c-RFA. Variables were selected based on existing literature or on their hypothetical contribution to poor initial regression based on our clinical observations. 5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Data was extracted from clinical charts and a self-administered patient questionnaire (Q) and recorded on standardized case record forms (CRF). Variables were dichomotous (yes/no) in case not otherwise specified. Patient characteristics were: age (years), gender, body mass index (weight/(length 2 )), history of GERD (Q), GERD duration (time from GERD diagnosis until first RFA, years, Q), antacids use duration (years, Q), current smoking (Q), smoking ever, alcohol abuse (male >3U/day; female >2 U/day, Q), diabetes mellitus (diabetes mentioned in the medical chart or antidiabetic medication), immune suppressant drugs use (inhalation corticosteroids, oral corticosteroids, or other immunosuppressant drugs), NSAIDs use (including acetylsalicylic acid), any medication use (besides antacids). BE characteristics were: BE duration (years since the first histological BE diagnosis), neoplasia duration (years since first histological diagnosis of LGD, HGD or carcinoma until first RFA), BE M-length (distance between upper end of the gastric folds and the proximal end of BE tongues, cm), BE C-length (distance between gastric folds and the upper end of the most proximal extent of the circumferential BE, cm), C&M difference (M-length minus C-length, cm), hiatal hernia length (cm), endoscopic signs of active reflux esophagitis (grade A, in case of grade ≥B, RFA was post-poned), ER scar regeneration with BE epithelium (versus regeneration with squamous epithelium), presence of BE islands in pre-RFA BE, presence of squamous islands in pre-RFA BE, 'bell shaped' esophagus (endoscopically visible proximal relative narrowing and distal relatively wide esophagus reported in the endoscopy report or CRF), relative narrowing pre-RFA (presence of a visible mild, asymptomatic stenosis or relative narrowing, reported in the endoscopy report or CRF: mild stricture = non-circumferential scarring; moderate stricture = circumferential scarring or stenosis; an endoscope can pass; severe stricture = stenosis, an endoscope cannot pass), most advanced histology prior to RFA (NDBE+LGD versus HGD in biopsies), most advanced histology prior to any endoscopic treatment (NDBE+LGD versus HGD+carcinoma). Treatment characteristics were: ER prior to RFA, RFA-balloon size, smallest esophageal inner diameter (EID; as measured during sizing prior to RFA), smallest EID minus RFA-balloon size.
Ethics, data collection and statistics
This prospective multicenter cohort study was superimposed on several European multicenter projects and IRB approved prospective RFA study protocols. 2, 3, 4, 6, 7 All patients signed informed consent. A cut-off value of <50% BE regression at 3 months after c-RFA was used to define 'poor initial responders'. Mean (±SD) was used for parametric distribution and median (inter-quartile range, IQR) for non-parametric distribution. Mann-Whitney U test, Chi-square test and Fisher exact test were used to compare groups where appropriate. Baseline variables associated with poor initial response in the univariate analysis with p<0.10 were subsequently entered in a multivariate regression model to detect potential predictive factors for a poor initial response to c-RFA. Odds ratios (OR) and 95%-confidence intervals (95%CI) were used to quantify the predictive associations. Pearson and Spearman's test were used to detect multicollinearity between predictors and in the case of a strong association (rho≥0.9) only one of the predictors was entered in the multivariate model. A simplified and robust version of the final multivariate model was created by counting the number of risk factors present, and providing the observed risk for the different categories (e.g. no risk factor present, one risk factor, two risk factors, etc.) Two-sided p-values were considered statistically significant if p≤0.05. The SPSS statistical software package (SPSS Inc.16.0.2, Chicago, IL, USA) was used for data analysis.
RESULTS

Patients
Between July 2005 to March 2010, 278 patients were consecutively included in 14 European centers. 2,3, 4,6,7 There were 219 males (79%), the mean age was 63 (SD 13) years, and the median BE length was C4M6 (IQR C2-8, M4-10). A prior ER was performed in 177 patients (64%). The overall most advanced histological diagnosis in biopsies and ER specimens was carcinoma in 116, HGD in 116, LGD in 44, and intestinal metaplasia without dysplasia in 2 patients (Table 1 ).
Barrett's surface area regression at 3 months follow-up
The median BE surface area regression 3 months after initial c-RFA of the whole cohort of 278 patients was 85% (IQR 60-95). BE surface area regression scores were based on the review score by the two expert endoscopists in 219 patients (79%), including 28 patients (10%) in whom the surface area regression score was established in a consensusmeeting. The median difference in BE regression percentage was 0% (IQR -5.0-7.0) when comparing endoscopist 1 minus endoscopist 2. In 59 patients (21%) the surface area regression score was based on the real-time estimation of the endoscopist at the 3 months endoscopy because endoscopic images were not representative or available. The median difference in BE regression percentage between the 'real time score' and the mean score of two endoscopists was 2.5% (IQR -5.0-10.0). 
Relevance of poor initial response to predict overall treatment results
Three months after c-RFA, 36 patients (13%) had a BE surface area regression <50% BE regression and were thus categorized as poor initial responders, 236 patients (78%) had a BE surface area regression ≥50% and were categorized as good initial responders. Six of 278 patients did not finish the treatment protocol for unrelated reasons (see below) ( Table 2 , Figure 1-2) . Of the poor initial responders, 14% (5/36) ultimately failed CR-neoplasia (vs. 2% (6/236) in good initial responders; p<0.01) and 33% (12/36) ultimately failed CR-IM (vs. 5% (12/236) in good initial responders, p<0.01). Of patients who ultimately failed CR-IM and CR-neoplasia, 50% and 46% respectively had a poor initial response to c-RFA.
Poor initial responders either discontinued treatment after c-RFA (10/36, 25% of poor initial responders versus 2/236, 1% of good initial responders, p<0.01) or required more RFA sessions and a longer treatment period as compared to good initial responders: poor initial responders required a median treatment period of 13 months (IQR 9-18) versus 7 months (IQR 4-10) for good initial responders (p<0.01), and median of 4 RFA sessions (IQR 4-5) versus 3 RFA sessions (IQR 2-4) for good initial responders (p<0.01). Treatment results: complete response for early neoplasia and IM Of 278 patients included in the study, 272 finished the treatment protocol. Six patients did not finish the treatment protocol for unrelated reasons: cardiac death, lung cancer death, renal failure, colon cancer, cardiac disease, and psychiatric disease. Overall, 261 of 272 available patients (96%) achieved CR-neoplasia and 248 of 272 patients (91%) achieved CR-IM, after a median of 3 RFA sessions (IQR2-4) .
Eleven patients finally failed to achieve CR-neoplasia. One patient died from inoperable esophageal adenocarcinoma 13 months after ER of a visible lesion demonstrating a T1sm1 carcinoma during the RFA treatment phase. Three patients underwent successful esophagectomy for persistent early neoplasia. Three patients required multiple additional ERs after RFA and had residual visible BE areas containing LGD. Two patients showed poor BE surface regression and poor healing after c-RFA. After the BE had healed only LGD was found and no further RFA was performed. Two other patients with HGD at baseline refused follow-up with biopsies after endoscopic eradication of BE with RFA, therefore CR-neoplasia/IM could not be confirmed.
Thirteen additional patients failed to achieve CR-IM during the treatment period. Eight patients demonstrated poor regression and/or slow healing. Three patients had complete endoscopic regression of their BE yet showed focal IM of the cardia. In one patient buried Barrett's glands were observed in a single biopsy during the first follow-up endoscopy. Finally, one patient refused further RFA treatment once biopsies of the residual BE showed no dysplasia.
In 22 patients who achieved CR-neoplasia and CR-IM, additional ER ('escape' ER) was performed to remove persisting BE after 5 RFA sessions (7 no IM, 6 IM, 3 LGD) or to remove a focal lesion during the RFA treatment phase (4 LGD, 1 HGD, 1 T1sm1).
Predictors for poor Barrett's surface regression at three months after c-RFA Univariate analysis detected 6 significant predictive factors for a poor initial response at 3 months after c-RFA: no NSAIDs use (OR=4.4; p=0.05); presence of active reflux esophagitis (OR=4.0; p=0.02); regeneration of ER scar with BE tissue (OR=3.4; p=0.04); relative esophageal narrowing (asymptomatic) pre-RFA (OR=3.2; p<0.01); absence of squamous islands pre-RFA (OR=2.9; p<0.01); and the number of years with neoplasia before RFA (OR=1.2; p=0.01) ( Table 1 ). There was no multicollinearity among variables. Multivariate analysis (Model-fit significance <0.01; Hosmer and Lemeshow Test significance 0.09, Nagelkerke R 2 0.31) demonstrated that presence of active reflux esophagitis (OR=37.4, p<0.01), regeneration of ER scar with BE tissue (OR=4.7; p=0.03) (Figure 3) , relative esophageal narrowing (asymptomatic) pre-RFA (OR=3.9; p=0.05), and the number of years with neoplasia before RFA (OR=1.2; p=0.03) were independent predictors of poor response at 3 months after c-RFA (Table 3 ). In our study, poor initial responders had a history of median 2 (IQR 2-6) years of neoplasia before c-RFA treatment vs. 1 (IQR 1-3) year for good responders. Baseline esophageal narrowing pre-RFA was present in 11/36 (31%) of poor responders vs. 29/242 (12%) of good responders. Regeneration of ER scar with BE tissue occurred in 5/21 (24%) of poor responders versus 11/132 (8%) of good responders. Signs of active reflux esophagitis prior to RFA despite PPI treatment were observed in 5/35 (14%) poor responders vs. 10/240 (4%) of good initial responders.
The predictive capability of the multivariable model can be illustrated by counting the number of risk factors present in each patient (Table 4) . In this analysis, the predictor 'years of neoplasia before c-RFA' was categorized in '≤2 years of neoplasia' and '>2 years of neoplasia'. The observed proportion of poor initial responders in the study population was 9% if none of the four independent predictors of poor response were present, whereas this was 13% in presence of 1 independent predictor, 38% in presence of 2 independent predictors and 100% in the presence of 3 independent predictors (p<0.00). This study suggests that regeneration of the ER scar with Barrett's epithelium is a predictor of poor initial response after circumferential balloon-based radiofrequency ablation (c-RFA).
DISCUSSION
Despite the good results of RFA for the ablation of dysplastic Barrett's esophagus, we have shown in this prospective multicenter study, that 13% of patients show poor regression of the BE surface at three months after the initial c-RFA session, and that these patients required more RFA sessions or a longer interval between RFA sessions to obtain complete healing of the esophagus. [1] [2] [3] [4] [5] [6] Additionally, this study demonstrates that these cases are more likely to ultimately fail to achieve complete response for IM or neoplasia. CR-neoplasia and CR-IM were as high as 98% and 95% respectively in good initial responders, in contrast, this was only 86% and 66% respectively in poor initial responders. Further, poor initial responders required a median treatment period of 13 months for 4 RFA-sessions, compared to 7 months for 3 RFA-sessions in good initial responders. This is the first study focusing on potential predictors of a poor response to RFA treatment early in the RFA treatment phase, which allows for an early change in the individual patient management. Our results show that a poor initial response after c-RFA may be predicted by presence of the certain baseline characteristics: active reflux esophagitis under PPI prior to RFA, regeneration of the ER scar with Barrett's epithelium, esophageal narrowing prior to RFA, or a longer history of Barrett's neoplasia prior to RFA. Remarkably, characteristics of the Barrett's esophagus were more important in predicting a poor response at 3 months after c-RFA than patient characteristics or technical aspects of RFA treatment.
The presence of active reflux esophagitis at baseline was the strongest predictor of a poor initial response after c-RFA. This is in agreement with two recent small studies in which patients underwent pH-impedance measurements prior to RFA: patients who failed to achieve CR-IM had a higher rate of reflux despite PPI treatment. 15, 21 These data suggest that ongoing reflux disease under PPI treatment may compromise the success rate of RFA. In our study, we did not systematically perform pH-studies. However, given our finding of active reflux esophagitis as a potential predictor of poor response, further research is required to study the clinical implications of uncontrolled reflux disease in patients scheduled for RFA. These studies should include pH-impendance measurements to assess the severity of GERD and its influence on the BE regression in RFA patients, including examination of the contents of the refluxate (bile acid, pancreatic juices). 15 If indeed the response to RFA treatment can be related to the quantification of esophageal reflux under double dose PPI, it may help to tailor medical and even surgical therapy (fundoplication) prior to RFA in order to increase the success rates of RFA. At this time, the study protocols used so far, adhered to an aggressive acid suppression regimen, consisting of esomeprazole 40 mg BID as a maintenance dosage, with the addition of ranitidine 300mg AN and sucralfate sachets QID during 2 weeks after every RFA session. [1] [2] [3] [4] [5] [6] In case of active reflux, it may be advisable -based on our results-to post-pone the RFA procedure and to optimize acid suppression and patient's compliance to medical treatment and life style advices. Further, in case of a poor initial response to RFA, a low threshold to pH-measurements and referral for Nissen fundoplication in patients with ongoing reflux or poor healing is advised during the RFA treatment phase. We detected two new predictors of response to RFA that are related to the esophageal regeneration capacity: regeneration of the ER wound with Barrett's instead of squamous epithelium (multivariate analysis) and the absence of squamous islands in the Barrett's segment (univariate analysis). We hypothesize that squamous regeneration of the ER scar and a high number of squamous islands in the Barrett's segment reflects a tendency of the BE segment to re-epithelialization with normal squamous cell mucosa after damage of the Barrett's epithelium. [22] [23] [24] [25] Presence of an asymptomatic relative narrowing or mild stenosis of the BE was an independent predictor of poor response in our study. These mild stenoses may influence the response to RFA by two mechanisms. First and most likely, these patients may be part of a subgroup of patients with more severe reflux as compared to others, since the narrowing may be caused by reflux-induced scarring. Second, it is conceivable that stenosis caused by scarring due to ER or reflux disease may result in suboptimal electrode contact and a less effective ablation. Additionally, RFA treatment may be suboptimal due to conservative balloon selection in patients with prior ER or reflux stenosis or scarring, since in these patients it is advised to use an ablation balloon with a diameter that is two sizes smaller than the smallest measurement to prevent laceration during RFA. 4 Our finding that a longer history of neoplasia was a predictor of poor BE surface regression comports with the results of others who demonstrated a relationship between longer history of neoplasia and failure for CR-IM. 5 In contrast, presence of BE alone for a longer time was not a predictor of poor response. Theoretically, neoplastic Barrett's epithelium has less optimal regeneration capacities than non-neoplastic BE.
A limitation of this study is the use of logistic regression analysis on a relative small number of patients with a poor initial response, therefore the relationships detected in our study may appear stronger than they are in a larger population. However, by selecting potential variables based on our clinical knowledge existing data, and by presenting the predictive capability of a simplified, robust version of the multivariable model, we aimed to reduce the influence of potential overfitting of the regression model. Nevertheless, our findings require external validation in other and larger study populations. Another limitation is that we have related potential predictive markers for response to a surrogate endpoint. We selected the BE surface regression after c-RFA to define efficacy, assuming that this endpoint is a better measure of the efficacy of c-RFA than the rates of CR-neoplasia and CR-IM after multiple RFA sessions. Furthermore, we evaluated the agreement among the 'real time' Barrett's regression percentage as scored during endoscopy and the surrogate endpoint of the mean Barrett's regression percentage scored by two experienced endoscopists by reviewing endoscopic images. The median difference among endoscopists and the 'real time' score was found to be small (2.5%). In addition, we used the mean score of both endoscopists as the primary endpoint, thus partially ruling out interobserver variation.
An important strength of our study is its multicenter design, with centers uniformly trained in RFA: either as a part of participation in several European multicenter studies, or as participants of the European ER&RFA training program initiated by our center (www. endosurgery.eu). [2] [3] [4] 6, 7 This ensured that all centers were proficient in RFA treatment for BE. Furthermore, this study contains a large number of patients, and patients were treated with RFA for a wide range of indications, such as HGD, LGD, non-dysplastic BE, BE≤5cm, BE≥10cm, and BE after ER of HGD or early carcinoma. All patients were prospectively registered using case registration forms that were available online. Another strength of the study is the blinded scoring of the Barrett's regression percentage at 3 months by two endoscopists independently, to validate the primary endpoint.
In conclusion, this prospective multicenter study showed that 13% of patients have less than 50% surface regression of their Barrett's esophagus after initial c-RFA. These 'poor initial responders' have significantly lower success rates, require more RFA sessions, and have a prolonged treatment period. Our results suggest that a poor initial response to c-RFA occurs more often in patients who regenerate their ER wound with BE, have endoscopic signs of active reflux esophagitis under PPI, have had neoplasia in BE for a longer time period prior to RFA or have a narrowing of their esophagus prior to RFA. These findings need to be confirmed in other large studies, focussing on the possible role of refractory reflux. Ultimately, this may help to stratify patients to alternative management strategies, including endoscopic surveillance, esophagectomy, stepwise radical endoscopic resection, or Nissen fundoplication followed by RFA.
